The Effectiveness of Mesenchymal Stem Cell-Derived Exosome Therapy in Improving Endothelial Dysfunction in Postpartum Mothers With a History of Preeclampsia

What this Trial Is About

Women who have experienced preeclampsia during pregnancy face a higher risk of heart disease later in life due to lasting damage to blood vessels. This trial evaluates whether a new treatment using mesenchymal stem cell-derived exosomes can help repair blood vessel damage in postpartum women with a history of preeclampsia. Preeclampsia causes high blood pressure and endothelial dysfunction, leading to serious long-term cardiovascular risks. Participants will receive either a single dose of exosome therapy or a placebo through an intravenous or intramuscular injection. The exosomes contain healing substances such as growth factors and microRNAs that may promote blood vessel repair. The study includes 80 women randomly assigned to receive either the treatment or placebo, with follow-up visits extending up to 24 months to monitor long-term effects. Women in the study will undergo blood tests, vital sign checks, and imaging to assess blood vessel function and health. Researchers will measure changes in endothelial function biomarkers, blood pressure, blood counts, and edema at baseline and one week after treatment. Safety and health will be closely monitored throughout the study period, including proteinuria and uterine artery function, to evaluate the treatment's impact on vascular repair and cardiovascular risk reduction.

MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction